Statements
databases
psp
cbn
pc
bel_lc
signor
biogrid
lincs_drug
tas
hprd
trrust
ctd
vhn
pe
drugbank
omnipath
conib
crog
dgi
|
rlimsp
isi
tees
geneways
eidos
trips
medscan
sparser
reach
reading
Dabrafenib affects BRAF
2
|
2
70
Dabrafenib affects ERK
|
2
39
Dabrafenib affects MAPK
|
19
Dabrafenib affects MPRIP
|
3
14
Dabrafenib affects vemurafenib
|
16
Sotrastaurin affects apoptotic process
|
1
13
Dabrafenib affects RAF1
1
|
13
Dabrafenib affects trametinib
|
13
Sotrastaurin affects GNAQ
|
13
Dabrafenib affects apoptotic process
|
1
1
10
Sotrastaurin affects PKC
|
1
4
7
|
1
11
|
1
1
1
8
Sotrastaurin affects NFkappaB
|
11
Momelotinib affects JAK2
1
1
|
3
6
Dabrafenib affects necroptotic process
|
2
9
Dabrafenib affects autophagy
|
11
Dabrafenib affects Melanoma
1
|
10
Dabrafenib affects MEK
|
11
Dabrafenib affects Neoplasm Invasiveness
|
10
Sotrastaurin affects ERK
|
1
9
Sotrastaurin affects PRKCQ
4
|
1
1
3
Sotrastaurin affects 2'-O-methyluridine
|
9
Dabrafenib affects RIPK3
|
4
5
Sotrastaurin affects activation
|
8
Sotrastaurin affects tacrolimus (anhydrous)
|
8
Dabrafenib affects Cell Survival
|
1
6
Dabrafenib affects CDK16
1
|
6
Sotrastaurin affects growth
|
1
5
Momelotinib affects JAK1
1
2
|
3
Dabrafenib affects endoplasmic reticulum
|
6
Dabrafenib affects CYP3A4
|
1
5
Sotrastaurin affects MARCKS
|
2
4
Sotrastaurin affects ACE2
|
2
4
Momelotinib affects STAT3
|
6
Dabrafenib affects extracellular matrix
|
6
Dabrafenib affects cell growth
|
1
5
Dabrafenib affects Neoplasms
|
6
Sotrastaurin affects PRKCB
3
2
|
1
Dabrafenib affects MAP2K1
|
6
Sotrastaurin affects PRKCD
3
|
2
Dabrafenib affects hPXR
|
2
1
2
Dabrafenib affects cell death
|
5
Dabrafenib affects cell cycle
|
1
4
Dabrafenib affects Multiple Myeloma
|
5
|
5
Sotrastaurin affects RASGRP3
|
5
Dabrafenib affects AKT
|
5
Sotrastaurin affects phosphorylation
|
4
Sotrastaurin affects PRKCE
3
|
1
Sotrastaurin affects PRKCA
3
|
1
Dabrafenib affects mtnN
|
4
Dabrafenib affects PTEN
|
4
Brivanib affects cell population proliferation
|
4
Sotrastaurin affects everolimus
|
4
Sotrastaurin affects cell cycle
|
4
Momelotinib affects Neoplastic Stem Cells
|
4
Momelotinib affects JAK
|
4
Dabrafenib affects RAF
|
4
A-674563 affects AKT
|
4
Sotrastaurin affects PKC isoforms
|
4
Dabrafenib affects TNF
1
|
3
Sotrastaurin affects cytokine production
|
1
2
Sotrastaurin affects RPS6
|
1
2
Sotrastaurin affects PRKCH
3
|
Sotrastaurin affects NFAT
|
1
2
Sotrastaurin affects GSK3B
2
|
1
Sotrastaurin affects ABC-DLBCL
|
3
Momelotinib affects apoptotic process
|
3
Dabrafenib affects TLE5
|
3
Dabrafenib affects NEK9
|
1
2
Dabrafenib affects MCL1
|
3
Dabrafenib affects CYP2C9
|
1
2
Brivanib affects Liver Cirrhosis
|
3
Y-39983 affects RHOA
|
3
Y-27632 affects Carcinoma, Renal Cell
|
3
KW2449 affects DNA Damage
|
3
Sotrastaurin affects IL2
|
3
Dabrafenib affects PTTG1
|
3
Dabrafenib affects NRAS
|
3
Dabrafenib affects DNA Damage
|
3
Y-27632 affects cell migration
|
3
Y-27632 affects apoptotic process
|
3
LY-2157299 affects TGFB
|
2
1
Sotrastaurin affects STAT3
|
3
Sotrastaurin affects MCL1
|
3
Sotrastaurin affects CASP3
|
3
Sotrastaurin affects AKT
|
3
Momelotinib affects STAT5
|
3
Dabrafenib affects MLKL
|
1
2
Sotrastaurin affects triple-negative breast cancer
|
2
Sotrastaurin affects superoxide
|
2
Sotrastaurin affects signaling
|
2
Sotrastaurin affects responses
|
2
Sotrastaurin affects psn6
|
2
Sotrastaurin affects lysis
|
2
Sotrastaurin affects lipopolysaccharide
|
2
Sotrastaurin affects activity
|
2
Sotrastaurin affects PKC-mediated early T cell
|
2
Sotrastaurin affects PIM1
2
|
Sotrastaurin affects MAPK
|
2
Sotrastaurin affects JAK3
2
|
Sotrastaurin affects Infections
|
2
Sotrastaurin affects IL2RA
|
2
Sotrastaurin affects IL17A
|
1
1
Sotrastaurin affects IFNG
|
2
Sotrastaurin affects FOXP3
|
2
Sotrastaurin affects CDK2
2
|
Sotrastaurin affects BCL2L1
|
2
Momelotinib affects p65 phosphorylation
|
2
Momelotinib affects Primary Myelofibrosis
|
2
Momelotinib affects Met-Phe
|
2
Momelotinib affects JAK3
1
|
1
Momelotinib affects ACVR1
1
|
1
Lestaurtinib affects virus genome copy
|
2
Lestaurtinib affects viral early late proteins
|
2
Lestaurtinib affects late HAdV-4 HAdV-7
|
2
Dabrafenib affects ptc
|
2
Dabrafenib affects progression-free survival
|
2
Dabrafenib affects necrotic cell death
|
1
1
Dabrafenib affects metastatic melanoma
|
2
Dabrafenib affects inflammatory response
|
2
Dabrafenib affects hydroxychloroquine
|
1
1
Dabrafenib affects cellular senescence
|
2
Dabrafenib affects brain metastases
|
2
Dabrafenib affects VCAM1
2
|
Dabrafenib affects SELE
2
|
Dabrafenib affects PRC1
|
2
Dabrafenib affects PLX-4720
|
2
Dabrafenib affects PARP1
|
2
Dabrafenib affects Neoplasm Metastasis
|
2
Dabrafenib affects ICAM1
2
|
Dabrafenib affects Death
|
2
Dabrafenib affects CYCS
|
2
Dabrafenib affects CDKN1A
|
2
Dabrafenib affects BRAF inhibitors
|
2
Brivanib affects growth factor
|
2
Brivanib affects FGF
|
2
Y-27632 affects Rho kinase (ROCK
|
2
Y-27632 affects Cell Survival
|
1
1
LY-2157299 affects cell migration
|
2
LY-2157299 affects TGFBR1
2
|
LY-2157299 affects TGFBR
|
2
LY-2157299 affects Cholangiocarcinoma
|
2
A-674563 affects cell cycle
|
2
Sotrastaurin affects PTPN22
|
1
1
Sotrastaurin affects Neoplasms
|
2
|
2
Sotrastaurin affects Cyclin
|
2
Sotrastaurin affects CDKN1B
|
2
Momelotinib affects STAT
|
2
Momelotinib affects LY6G6D
|
2
Dabrafenib affects phospho-MEK
|
2
Dabrafenib affects iodide
|
2
Dabrafenib affects diiodine
|
2
Dabrafenib affects cobimetinib
|
2
Dabrafenib affects casE
|
2
Dabrafenib affects STING1
|
1
1
Dabrafenib affects SLC5A5
|
1
1
Dabrafenib affects JNK
|
2
Dabrafenib affects Caspase
|
1
1
Y-27632 affects cell differentiation
|
1
1
Y-27632 affects MSN
|
2
Y-27632 affects Hypertension
|
1
1
LY-2157299 affects angiogenesis
|
1
1
LY-2157299 affects TGFB1
|
1
1
KW2449 affects reactive oxygen species
|
2
KW2449 affects apoptotic process
|
2
KW2449 affects Histone_H3
|
2
A-674563 affects AKT2
|
2
Sotrastaurin affects tacrolimus inasmuch
|
1
|
1
Sotrastaurin affects recovered cell culture media
|
1
Sotrastaurin affects raloxifene
|
1
Sotrastaurin affects pMEK
|
1
Sotrastaurin affects obsolete ribosomal RNA
|
1
Sotrastaurin affects nPKC isoforms
|
1
Sotrastaurin affects morphine(1+)
|
1
Sotrastaurin affects mAPOBEC3
|
1
Sotrastaurin affects expression
|
1
Sotrastaurin affects dimethyl sulfoxide
|
1
Sotrastaurin affects cell adhesion
|
1
Sotrastaurin affects catalytic activity
|
1
Sotrastaurin affects calcium(2+)
|
1
Sotrastaurin affects cPKC
|
1
Sotrastaurin affects branching
|
1
Sotrastaurin affects autophosphorylation
|
1
Sotrastaurin affects activation PKCtheta TBK1
|
1
Sotrastaurin affects XIAP
|
1
Sotrastaurin affects Treg
|
1
Sotrastaurin affects Tconv
|
1
Sotrastaurin affects TCR
|
1
Sotrastaurin affects TBK1
|
1
Sotrastaurin affects STK3
1
|
Sotrastaurin affects SLK
1
|
Sotrastaurin affects SGK2
1
|
Sotrastaurin affects SGCB
|
1
Sotrastaurin affects S473-Akt
|
1
Sotrastaurin affects RPS6KB1
1
|
Sotrastaurin affects RPS6KA3
1
|
Sotrastaurin affects RB1
|
1
Sotrastaurin affects Psoriasis
1
|
Sotrastaurin affects Proteasome
|
1
Sotrastaurin affects Pkcdelta
|
1
Sotrastaurin affects PRKG1
1
|
Sotrastaurin affects PRKCI
1
|
Sotrastaurin affects PRKCG
1
|
Sotrastaurin affects PRKAA1
1
|
Sotrastaurin affects PLK1
1
|
Sotrastaurin affects PKN2
1
|
Sotrastaurin affects PKCs
|
1
Sotrastaurin affects PKCetaat
|
1
Sotrastaurin affects PKCalpha, beta, delta
|
1
Sotrastaurin affects PKCalpha and delta
|
1
Sotrastaurin affects PKC-NF-kappaB
|
1
Sotrastaurin affects PKC kinase
|
1
Sotrastaurin affects PIM3
1
|
Sotrastaurin affects PIM2
1
|
Sotrastaurin affects PCNA
|
1
Sotrastaurin affects PARP1
|
1
Sotrastaurin affects Nutlin-3
|
1
Sotrastaurin affects Neoplasm Invasiveness
|
1
Sotrastaurin affects NUAK2
1
|
Sotrastaurin affects Melanoma
|
1
Sotrastaurin affects MST1R
1
|
Sotrastaurin affects MSC
|
1
Sotrastaurin affects MINK1
1
|
Sotrastaurin affects MDM2-p53
|
1
Sotrastaurin affects MAP4K5
1
|
Sotrastaurin affects MAP4K4
1
|
Sotrastaurin affects IKKalpha/beta
|
1
Sotrastaurin affects IKB
|
1
Sotrastaurin affects GSK3A
1
|
Sotrastaurin affects GRK5
1
|
Sotrastaurin affects GNA11
|
1
Sotrastaurin affects G1 arrest
|
1
Sotrastaurin affects FUT2
|
1
Sotrastaurin affects FER
1
|
Sotrastaurin affects EIF4EBP1
|
1
Sotrastaurin affects EIF4E
|
1
Sotrastaurin affects EGF-stimulated association TBK1 CARD10 PKCtheta
|
1
Sotrastaurin affects EGF
|
1
Sotrastaurin affects Cell Survival
|
1
Sotrastaurin affects CILK1
1
|
Sotrastaurin affects CD86
|
1
Sotrastaurin affects CD80
|
1
Sotrastaurin affects CD8 T-cell function
|
1
Sotrastaurin affects CD69
|
1
Sotrastaurin affects CAMK2G
1
|
Sotrastaurin affects CAMK2D
1
|
Sotrastaurin affects BIRC5
|
1
Sotrastaurin affects BCL2A1
|
1
Sotrastaurin affects BCL2
|
1
Sotrastaurin affects APOBEC3B
|
1
Sotrastaurin affects AP1
|
1
Sotrastaurin affects ANXA5
|
1
Sotrastaurin affects ACE2 shedding D-glucose
|
1
Sorafenib affects dabrafenib
|
1
Regorafenib affects dabrafenib
|
1
Recombinant hPXR affects dabrafenib
|
1
Pregabalin affects dabrafenib
|
1
Palbociclib affects dabrafenib
|
1
Nintedanib affects dabrafenib
|
1
Nilotinib affects dabrafenib
|
1
Momelotinib affects viral yield
|
1
Momelotinib affects temozolomide
|
1
Momelotinib affects signaling
|
1
Momelotinib affects responses post-ruxolitinib setting
|
1
Momelotinib affects reactive oxygen species
|
1
Momelotinib affects protein IkappaBalpha phosphorylated
|
1
Momelotinib affects phosphorylation p65 TGEV infected ST cells
|
1
Momelotinib affects malignant hematological cells
|
1
Momelotinib affects mTOR inhibitor
|
1
Momelotinib affects induction IL-6
|
1
Momelotinib affects hepatic hepcidin
|
1
Momelotinib affects expression
|
1
Momelotinib affects endoplasmic reticulum
|
1
Momelotinib affects dose dependent PSA AR mRNA protein LNCaP cells
|
1
Momelotinib affects bone morphogenic protein receptor kinase activin A receptor
|
1
Momelotinib affects activation
|
1
Momelotinib affects TGFBR1
1
|
Momelotinib affects TBK1
|
1
Momelotinib affects STING perinuclear foci parental Rab7-WT Rab7-S72A expressing MDA-MB-468 cells
|
1
Momelotinib affects STAT1
|
1
|
1
Momelotinib affects Rab7-S72E cells
|
1
Momelotinib affects RIOK3
1
|
Momelotinib affects Phosphorylation
|
1
Momelotinib affects NFkappaB
|
1
Momelotinib affects MYLK4
1
|
Momelotinib affects MYC
|
1
Momelotinib affects IGF1R
|
1
Momelotinib affects IGF1
|
1
Momelotinib affects IGF1 receptor
|
1
Momelotinib affects IC 50 18 nm
|
1
Momelotinib affects IC 50 11 nm
|
1
Momelotinib affects IC 50 0.16 muM
|
1
Momelotinib affects HAMP
|
1
Momelotinib affects ERK
|
1
Momelotinib affects CHUK
1
|
Momelotinib affects BMPR1B
1
|
Momelotinib affects BMPR1A
1
|
Lestaurtinib affects virus yield
|
1
Lestaurtinib affects virus yield infected cells.A549 cells
|
1
Lestaurtinib affects pro-inflammatory transcription NFkappaB
|
1
Lestaurtinib affects penton HAdV
|
1
Lestaurtinib affects outcome
|
1
Lestaurtinib affects late Figure HAdV-5
|
1
Lestaurtinib affects infected vehicle-treated cells
|
1
Lestaurtinib affects genome copy
|
1
Lestaurtinib affects genome copy Fig. late Fig. HAdV-5
|
1
Lestaurtinib affects Leukemia, Myeloid, Acute
1
|
Lestaurtinib affects JAK2
|
1
Lestaurtinib affects FLT3
|
1
Lestaurtinib affects 2-log genome copy treated cells hpi
|
1
Lestaurtinib affects % muM
|
1
Lapatinib affects dabrafenib
|
1
Ibrutinib affects dabrafenib
|
1
Gefitinib affects dabrafenib
|
1
Erlotinib affects dabrafenib
|
1
Dabrafenib affects signal transduction
|
1
Dabrafenib affects robust apoptosis cancer cells harboring BRAF V600E TERT mutations
|
1
Dabrafenib affects response to stress
|
1
Dabrafenib affects propidium iodide
|
1
Dabrafenib affects patient survival
|
1
Dabrafenib affects paracetamol
|
1
Dabrafenib affects overall survival
|
1
Dabrafenib affects nuclear factor-kappaB
|
1
Dabrafenib affects mek
|
1
Dabrafenib affects liver injury
|
1
Dabrafenib affects immune response
|
1
Dabrafenib affects hexadecane
|
1
Dabrafenib affects glucose
|
1
Dabrafenib affects gemcitabine
|
1
Dabrafenib affects extracellular signal-related kinase
|
1
Dabrafenib affects estrone 3-sulfate
|
1
Dabrafenib affects ear
|
1
Dabrafenib affects cutaneous squamous-cell carcinoma
|
1
Dabrafenib affects cutaneous squamous cell carcinoma
|
1
Dabrafenib affects cuSCC/KA
|
1
Dabrafenib affects complete response
|
1
Dabrafenib affects cerium
|
1
Dabrafenib affects cell
|
1
Dabrafenib affects cell migration
|
1
Dabrafenib affects cell adhesion
|
1
Dabrafenib affects axitinib
|
1
Dabrafenib affects anti-BRAF
|
1
Dabrafenib affects WMD1
|
1
Dabrafenib affects VEGFA
|
1
Dabrafenib affects VEGF
|
1
Dabrafenib affects UGT1A1
|
1
|
1
Dabrafenib affects TYRP1
|
1
Dabrafenib affects TSHR
|
1
Dabrafenib affects TPO
|
1
Dabrafenib affects TGFBR1
1
|
Dabrafenib affects TGFBI
1
|
Dabrafenib affects TG
|
1
Dabrafenib affects TESK1
1
|
Dabrafenib affects TERT
|
1
Dabrafenib affects Small Cell Lung Carcinoma
|
1
Dabrafenib affects SRMS
1
|
Dabrafenib affects SLC2A3
|
1
Dabrafenib affects SLC2A1
|
1
Dabrafenib affects RELA
1
|
Dabrafenib affects RAS-RAF-MEK-ERK
|
1
Dabrafenib affects RAS
|
1
Dabrafenib affects RAF/MEK/ERK
|
1
Dabrafenib affects RAC1
|
1
Dabrafenib affects PTPN11
|
1
Dabrafenib affects PPP1R13L
|
1
Dabrafenib affects PPARG
|
1
Dabrafenib affects PLK4
1
|
Dabrafenib affects PIK3C2B
1
|
Dabrafenib affects PGR
|
1
Dabrafenib affects PERK12
|
1
Dabrafenib affects PDCD1
|
1
Dabrafenib affects NT5E
|
1
Dabrafenib affects NSP9
|
1
Dabrafenib affects NR1I3
|
1
Dabrafenib affects NR1I2
|
1
Dabrafenib affects NGFR
|
1
Dabrafenib affects NFE2L2
|
1
Dabrafenib affects MMP9
|
1
Dabrafenib affects MAPK3
1
|
Dabrafenib affects MAPK1
1
|
Dabrafenib affects MAP4K5
|
1
Dabrafenib affects MAP2K4
|
1
Dabrafenib affects MAP2K2
|
1
Dabrafenib affects MAP2K
|
1
Dabrafenib affects Lys-Ser
|
1
Dabrafenib affects Lung Neoplasms
|
1
Dabrafenib affects LIMK2
1
|
Dabrafenib affects KRAS
|
1
Dabrafenib affects KIT
|
1
Dabrafenib affects KDR
|
1
Dabrafenib affects Interferon
|
1
Dabrafenib affects ITGB5
1
|
Dabrafenib affects ITGAV
1
|
Dabrafenib affects IRF3
|
1
Dabrafenib affects IL6
|
1
Dabrafenib affects HR
|
1
Dabrafenib affects HK2
|
1
Dabrafenib affects GPT
1
|
Dabrafenib affects GLUT1
|
1
Dabrafenib affects GIST case
|
1
Dabrafenib affects F3
|
1
Dabrafenib affects ERBB3
|
1
Dabrafenib affects EIF2AK3
|
1
Dabrafenib affects EGFR inhibitors
|
1
Dabrafenib affects E2F4
|
1
Dabrafenib affects E2F1
|
1
Dabrafenib affects DNA repair
|
1
Dabrafenib affects D-dimer
|
1
Dabrafenib affects Counting Kit-8
|
1
Dabrafenib affects CSK
1
|
Dabrafenib affects CSF3
|
1
Dabrafenib affects CRC
|
1
Dabrafenib affects CRAF-CRY2
|
1
Dabrafenib affects CRAF-CIBN
|
1
Dabrafenib affects CRAF-CIBN fusion proteins
|
1
Dabrafenib affects COQ8B
1
|
Dabrafenib affects COQ8A
1
|
Dabrafenib affects CHEK1
|
1
Dabrafenib affects CDKN1B
|
1
Dabrafenib affects CDK18
1
|
Dabrafenib affects CDK17
1
|
Dabrafenib affects CD8
|
1
Dabrafenib affects CD3
|
1
Dabrafenib affects CCND1
|
1
Dabrafenib affects CASP3
|
1
Dabrafenib affects BREAK trials
|
1
Dabrafenib affects BRAFV600E orBRAFV600K mutation
|
1
Dabrafenib affects BRAFV600E mutation
|
1
Dabrafenib affects BRAF-wild-type
|
1
Dabrafenib affects BRAF-i+MEK-i
|
1
Dabrafenib affects BRAF-MEK
|
1
Dabrafenib affects BRAF melanoma cell lines
|
1
Dabrafenib affects BRAF inhibitor
|
1
Dabrafenib affects BIRC2
|
1
Dabrafenib affects B-Raf inhibitor
|
1
Dabrafenib affects B-Raf 34
|
1
Dabrafenib affects B-RAF kinase]
|
1
Dabrafenib affects ATP
|
1
Dabrafenib affects ARAF
|
1
Dabrafenib affects A375VR4
|
1
Dabrafenib affects 3D
|
1
Dabrafenib affects 2,4-difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide
|
1
Dabrafenib affects N,N'-(hexane-1,6-diyl)bis(1-\{(2S)-2-cyclohexyl-2-[(N-methyl-L-alanyl)amino]acetyl\}-L-prolyl-beta-phenyl-L-phenylalaninamide)
|
1
Brivanib affects liver injury
|
1
Brivanib affects hypoxia-induced migration tube microvascular endothelial cells
|
1
Brivanib affects growth factors
|
1
Brivanib affects VEGFA
|
1
Brivanib affects VEGF
|
1
Brivanib affects PDGFRB
|
1
Brivanib affects PDGF
|
1
Brivanib affects Neoplasms
|
1
Brivanib affects KDR
|
1
Brivanib affects FGFR
|
1
Y-39983 affects CWC22
|
1
Y-27632 affects µ
|
1
Y-27632 affects viral RNA replication
|
1
Y-27632 affects viral RNA release
|
1
Y-27632 affects tongue squamous cell carcinoma
|
1
Y-27632 affects survival
|
1
Y-27632 affects survival growth PSCs
|
1
Y-27632 affects stress fibers cultured cells
|
1
Y-27632 affects stress fiber
|
1
Y-27632 affects spindle formation
|
1
Y-27632 affects signal transduction
|
1
Y-27632 affects p-Tyr216 GSK-3beta
|
1
Y-27632 affects p-Ser422 Tau
|
1
Y-27632 affects only fibrosis
|
1
Y-27632 affects neutrophil adhesion
|
1
Y-27632 affects motor function
|
1
Y-27632 affects mitochondrial respiration
|
1
Y-27632 affects migration corneal endothelial cells
|
1
Y-27632 affects intraocular pressure
|
1
Y-27632 affects internalization
|
1
Y-27632 affects inflammatory response
|
1
Y-27632 affects huntingtin toxicity
|
1
Y-27632 affects functional recovery
|
1
Y-27632 affects focal adhesion
|
1
Y-27632 affects filamentous connections cells
|
1
Y-27632 affects enhanced neurite outgrowth
|
1
Y-27632 affects effector kinase protein kinase
|
1
Y-27632 affects cytoskeleton rearrangement hyper-permeability HUVECs induced TNF-alpha
|
1
Y-27632 affects corneal wound healing
|
1
Y-27632 affects contraction HASMCs
|
1
Y-27632 affects contractility in human airway smooth muscle cells
|
1
Y-27632 affects contractile force tracheal smooth muscle guinea pig
|
1
Y-27632 affects chemotaxis of the cells
|
1
Y-27632 affects cellular migration
|
1
Y-27632 affects cell-cell junction
|
1
Y-27632 affects cell population proliferation
|
1
Y-27632 affects cell motility
|
1
Y-27632 affects cell migration and adhesion
|
1
Y-27632 affects cell death
|
1
Y-27632 affects cAMP-dependent protein kinase concentrations.27
|
1
Y-27632 affects bicellular tight junction
|
1
Y-27632 affects axonal growth
|
1
Y-27632 affects arctiin-induced VEGF
|
1
Y-27632 affects anoikis
|
1
Y-27632 affects actomyosin
|
1
Y-27632 affects actin-stress fiber formation
|
1
Y-27632 affects actin cytoskeleton
|
1
Y-27632 affects actin cytoskeleton organization
|
1
Y-27632 affects a-SMA
|
1
Y-27632 affects Y-27632.67Similarly
|
1
Y-27632 affects Wounds and Injuries
|
1
Y-27632 affects VCL
|
1
Y-27632 affects TNF
|
1
Y-27632 affects TJP1
|
1
Y-27632 affects TGEV binding
|
1
Y-27632 affects RhoA downstream effector
|
1
Y-27632 affects Rho-associating protein kinase
|
1
Y-27632 affects Rho-associated kinase
|
1
Y-27632 affects Rho-associated kinase pathway
|
1
Y-27632 affects Rho-associated coiled-coil containing protein kinase (ROCK
|
1
Y-27632 affects Rho associated kinase
|
1
Y-27632 affects Relaxation
|
1
Y-27632 affects ROCK signaling pathway
|
1
Y-27632 affects RDX
|
1
Y-27632 affects RAC1
|
1
Y-27632 affects Protein Kinases
|
1
Y-27632 affects Progeria
|
1
Y-27632 affects PTHLH
|
1
Y-27632 affects PI3K
|
1
Y-27632 affects PFN
|
1
Y-27632 affects Neoplasm Metastasis
|
1
Y-27632 affects NFkappaB
|
1
Y-27632 affects MOVEMENT
|
1
Y-27632 affects MAPK3
|
1
Y-27632 affects MAPK1
|
1
Y-27632 affects Liver Neoplasms
|
1
Y-27632 affects Leukemia, Basophilic, Acute
|
1
Y-27632 affects LIMK2
|
1
Y-27632 affects LIM-kinase
|
1
Y-27632 affects Integrins
|
1
Y-27632 affects INS
|
1
Y-27632 affects IL1B
|
1
Y-27632 affects IL12B
|
1
Y-27632 affects I-kappa B kinase
|
1
Y-27632 affects Huntington Disease
|
1
Y-27632 affects G0 G1 phase cell cycle
|
1
Y-27632 affects Fig. 3A
|
1
Y-27632 affects FAT4
|
1
Y-27632 affects F2
|
1
Y-27632 affects EZR
|
1
Y-27632 affects ERK
|
1
Y-27632 affects CTNND1
|
1
Y-27632 affects CCL2
|
1
Y-27632 affects Axon growth
|
1
Y-27632 affects Alzheimer Disease
|
1
Y-27632 affects Acetylcholine-evoked contraction
|
1
Y-27632 affects ARHGEF17
|
1
Y-27632 affects AHCYL1
|
1
LY-2157299 affects liver remodeling
|
1
LY-2157299 affects cytokine secretion CAR T cells T cells
|
1
LY-2157299 affects chimeric antigen receptor-modified T cell function
|
1
LY-2157299 affects cell invasion
|
1
LY-2157299 affects WNT16
|
1
LY-2157299 affects TGFβRI
|
1
LY-2157299 affects TGFBR2
1
|
LY-2157299 affects SMAD2
|
1
LY-2157299 affects Raw264.7 cells
|
1
LY-2157299 affects RIPK2
1
|
LY-2157299 affects MAPK14
1
|
LY-2157299 affects KDR
1
|
LY-2157299 affects EsoAd1 ALK7
|
1
LY-2157299 affects COL2A1
1
|
LY-2157299 affects CD8
|
1
LY-2157299 affects ACVR1B
1
|
LY-2157299 affects ACAN
1
|
KW2449 affects vorinostat
|
1
KW2449 affects aurora kinases
|
1
KW2449 affects SNDX-275
|
1
KW2449 affects I836L+D
|
1
KW2449 affects HDACIs
|
1
KW2449 affects HDACI
|
1
KW2449 affects D835L+K
|
1
KW2449 affects C8orf44-SGK3
1
|
A-674563 affects ceramide
|
1
A-674563 affects cell population proliferation
|
1
A-674563 affects cell growth
|
1
A-674563 affects caspase-3/9
|
1
A-674563 affects apoptotic process
|
1
A-674563 affects TBC1D4
|
1
A-674563 affects SPHK1
|
1
A-674563 affects RPS6
|
1
A-674563 affects MDM2
|
1
A-674563 affects Caspase
|
1
A-674563 affects BUB1B-PAK6
1
|